Ad
related to: enzyme replacement therapy for lysosomal storage diseases paper cell model
Search results
Results from the WOW.Com Content Network
Once inside the body the vector introduces the therapeutic gene into host cells, and the protein encoded by the newly inserted gene is then produced by the body's own cells. [11] This type of therapy can correct for the missing protein/enzyme in patients with lysosomal storage diseases. [1] Hematopoietic stem cell (HSC) transplantation is ...
The M6P-tagged lysosomal enzymes are shipped to the late endosomes via vesicular transport. [1] Enzyme replacement therapy (ERT) for several lysosomal storage diseases relies on this pathway to efficiently direct synthetic enzymes to the lysosome where each can metabolize its particular substrate. [2]
Examples of lysosomal storage disorders include Gaucher's disease, Tay–Sachs disease, Sandhoff disease, and Sanfilippo syndrome. In a metabolic or genetic pathway, enzymes catalyze a series of reactions. Each enzyme is regulated or mediated by one gene through its RNA and protein products. At each phase in the pathway, enzyme activity ...
Lysosomal storage diseases (LSDs; / ˌ l aɪ s ə ˈ s oʊ m əl /) are a group of over 70 rare inherited metabolic disorders that result from defects in lysosomal function. [1] [2] Lysosomes are sacs of enzymes within cells that digest large molecules and pass the fragments on to other parts of the cell for recycling.
Alglucosidase alfa, sold under the brand name Myozyme among others, is an enzyme replacement therapy (ERT) orphan drug for treatment of Pompe disease (Glycogen storage disease type II), a rare lysosomal storage disorder (LSD). [6] Chemically, the drug is an analog of the enzyme that is deficient in patients affected by Pompe disease, alpha ...
[21] [22] [23] These were the first-ever enzyme replacement therapy (ERT) treatments for lysosomal diseases, and directly led to great advances in the development of enzyme replacement therapies for some of the other lysosomal diseases, by many different researchers who were inspired by Dr. Brady. (An international research and development ...
Cholesteryl Ester Storage Disease, presenting in pediatric and adult patients; Around 2010 both presentations came to be known as LAL-D, as both are due to a deficiency of the LAL enzyme. [3] In 2015 an enzyme replacement therapy, sebelipase alfa, was approved in the US and EU for the treatment of human LAL enzyme deficiency. [13]
As of March 2022, three medical drugs based on enzyme replacement therapy are available for Fabry disease: Agalsidase alfa, sold under the brand name Replagal by the company Takeda (since its acquisition of the company Shire), is a recombinant form of alpha-galactosidase A [21] It received approval in the EU in 2001. [22]
Ad
related to: enzyme replacement therapy for lysosomal storage diseases paper cell model